Alembic Pharma Q1 FY27 Earnings Call — Analysis (NSE: APLLTD)
Alembic Pharma raises FY27 revenue growth outlook to mid-teen, driven by upgraded US generics guidance to mid-to-high teens and broad-based Q1 momentum
Result quality: stable — Steady quarter. Management sentiment: optimistic.
The take
Q1FY27 Consolidated Revenue ₹2,150 Cr ( +26% YoY ) . New guidance — FY27 us generics revenue growth mid-to-high teens . New story: US generics momentum and guidance upgrade .
Results
Q1FY27: consolidated revenue ₹2,150 Cr +26% YoY; EBITDA ₹348 Cr +21% YoY (margin 16%); PAT ₹173 Cr +12% YoY; US generics +49% YoY
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹2,150 Cr | +26% | yoy · Q1FY27 |
| EBITDA | ₹348 Cr | +21% | yoy · Q1FY27 |
| EBITDA Margin | 16% | none · Q1FY27 | |
| Profit Before Tax | ₹223 Cr | +17% | yoy · Q1FY27 |
| Profit After Tax | ₹173 Cr | +12% | yoy · Q1FY27 · tax rate 22% vs 19% in Q1FY26 |
| R&D Expenditure | ₹186 Cr | point_in_time · Q1FY27 · 9% of revenue | |
| US Generics Revenue Growth | 49% | +49% | yoy · Q1FY27 · INR terms |
| India Branded Revenue Growth | 7% | +7% | yoy · Q1FY27 |
| International Generics (ex-US) Revenue Growth | 37% | +37% | yoy · Q1FY27 |
| API Business Revenue Growth | 33% | +33% | yoy · Q1FY27 |
| Animal Health Revenue Growth | 24% | +24% | yoy · Q1FY27 · within India branded business |
Guidance
FY27 overall revenue growth revised to closer to mid-teen from low double-digit; US generics now expected mid-to-high teens (vs low-to-mid teens); other segment guidance intact
What management committed to
- US generics business revenue growth for FY27 is now expected to be mid-to-high teens, up from earlier low-to-mid teens guidance, subject to normal market conditions and continued execution. — mid-to-high teens, FY27
- Consolidated revenue growth for FY27 is now expected to be closer to the mid-teen range (up from earlier low-double-digit guidance). — closer to the mid-teen range, FY27
- India branded business revenue growth in FY27 is expected to align close to market growth, in the high single digits. — high single digit, FY27
- Ex-US (ROW) international generics business revenue growth in FY27 is expected to be about 15% in INR terms. — about 15%, FY27
- API business revenue growth in FY27 is expected to be around 10%. — around 10%, FY27
- The US branded specialty business (Pivya and complementary products) is expected to start contributing positively to profit from next financial year (FY28) onwards, with the drag reducing gradually and trending towards breakeven by end of FY27. — positive contribution to profit, FY28
- The US branded business will cause approximately 150 basis points of dilution in consolidated EBITDA margin for full year FY27. — 150 basis points, FY27
- Alembic expects to launch approximately 15 additional products in the US generics segment during the remainder of FY27. — another 15-odd products, FY27
- In FY28, [Alembic] expects to see a similar number of US generics launches as in FY27, which will help offset erosion and support growth. — similar number of launches, FY28
- Gross debt will be reduced from current levels (₹1,600 Cr) to at least March levels and further towards approximately 1x EBITDA, as receivables unwind. — close to 1x of EBITDA, Q3FY27
Key themes
US generics momentum and guidance upgrade
How the narrative shifted
- US generics momentum and guidance upgrade: Management raised FY27 US generics growth guidance to mid-to-high teens, citing strong volume growth, Bosutinib exclusivity, and a robust launch pipeline; ex-Bosutinib growth was still over 25%, showing broad momentum.
- US branded specialty ramp and margin dilution: The newly launched US branded women's health franchise (Pivya) is in soft-launch phase; investments will drag margins by ~150 bps in FY27 but management expects a J-curve positive contribution from FY28.
- India branded business execution reset: India human health growth lags the market at 7%; new sales head appointed to drive grassroots execution, improve field productivity, and strengthen chronic portfolio, with results expected in 1-2 quarters.
- Operating leverage driving margin resilience: Core business margins are improving to high-teens due to volume growth, better asset utilization, and cost absorption; overall reported margin remains flattish only because of US branded investments.
- R&D and complex pipeline investment: R&D spend at 9% of revenue is directed towards peptide development, exhibit batches, and regulatory filings, aiming to build a differentiated pipeline for sustained US growth.
- Working capital normalization and debt reduction: Temporary spike in receivables due to higher sales pushed up debt; management expects unwinding in the next two quarters and a return to near 1x EBITDA leverage.
Operational commentary
- US generics volume-led growth; Bosutinib launched in June with 180-day exclusivity on 100/500mg strengths, contributing one month; ex-Bosutinib growth ~25%
- Seven new product launches in Q1; 4 ANDA filings, 10 approvals; ~15 more launches expected over the remainder of FY27
- US branded specialty business (women's health) commenced soft launch of Pivya; two smaller complementary products licensed; Pivya sourced from CMO, no manufacturing capex
- India branded business: new Sales & Marketing Head (Ramesh Juneja) brought in to drive execution reset; specialty therapies (Gynae, Gastro, Ophthal) performing well; acute and certain divisions dragging growth
- Animal Health delivered 24% growth; focus on operational efficiency and field productivity
- API business grew 33% YoY volume-led; guidance for ~10% full-year growth remains on track
- Ex-US (ROW) international generics grew 37%; new territory openings (Latin America, JV in Saudi Arabia, Canada)
- Manufacturing: preventive debottlenecking and upgrade of ophthalmic facility expanded capacity without incremental capex; short-term under-absorption in Q1
- R&D spend ₹186 Cr (9% of revenue), driven by peptide development, exhibit batches, and regulatory filings; focused on complex and differentiated pipeline
Analyst Q&A
Q. Timeline for US branded portfolio (Pivya) to contribute positively to EBITDA
Soft launch; should start to see a trend towards second half of the year, positive contribution next financial year onwards. Will gradually see reduction in drag, breakeven trend by end of FY27.
Q. Clarity on FY27 EBITDA margin trajectory given upgraded revenue guidance
Core margins improving to high-teens; US branded dilution ~150 bps. Overall margin maintained at similar trajectory; it may be a few percentage points better than FY26, directionally better operating leverage.
Q. Sustainability of Bosutinib revenue beyond the exclusivity period
Tough to say. Exclusivity until November, so Q2 and part of Q3 should see some sales. After that, if competition comes, it will be quite drastic because volumes are very small. Cannot guide beyond November.
Q. Why gross margins were flattish QoQ despite Bosutinib launch
Solvent prices up due to Middle East issues, product mix, and one-time under-absorption from preventive maintenance shutdown at ophthalmic facility. Still within guided 70-75% range.
Q. Increase in debt and interest cost; outlook for working capital
Gross debt ₹1,600 Cr, higher due to receivables from higher sales. Receivables to unwind in next two quarters; debt should moderate to at least March levels, intention to scale down to close to 1x EBITDA.
Research and educational content only. Not investment advice.